AM-Pharma reports positive results from recAP Phase I trial for Acute Kidney Injury

AM-Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces the results of its Phase I trial with both single and multiple ascending doses, which demonstrate that recAP is safe and well tolerated at all doses.

In total 50 healthy male and female volunteers were included in the randomised, double-blind, placebo-controlled, first-in-human, single and multiple dose escalation study, to investigate safety, tolerability, and pharmacokinetics of recAP administered intravenously. Volunteers in the single dose groups were administered one of four single doses, and those in the multiple dose groups were administered one of two multiple doses on three consecutive days. No safety issues were observed, in any of the dose groups.

The trial also established recAP's pharmacokinetic properties. These include dose exposures up to and above the target therapeutic range as determined in AM-Pharma's earlier positive Phase II clinical trial results with bovine Alkaline Phosphatase (bovine AP), in the treatment of patients with Acute Kidney Injury (AKI).

"Our wealth of knowledge around Alkaline Phosphatase, gained from our earlier Phase II programmes with bovine AP, meant that at the start of this clinical trial we expected that recAP would be safe and well tolerated," said Erik van den Berg, CEO of AM-Pharma. "It is nevertheless very encouraging to see that recAP is showing favourable pharmacokinetics, and should therefore provide superior tissue distribution and extended half-life beyond that seen with bovine AP. With this confirmation, alongside the safety profile, we are confident that recAP is a promising candidate to show therapeutic efficacy in its Phase II development."

AM-Pharma is currently finalising the Phase II trial protocol, for recAP to treat AKI, which will take advantage of "Adaptive Trial Design" - an increasingly adopted, and regulatory-endorsed, methodology that allows predefined modifications and expansion of a trial based on initial study results. Adaptive Trial Design increases the chances to obtain statistically relevant data to validate clinical products, and thus shorten product development times.

Source:

AM-Pharma B.V.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New genetic insights reveal kidney disease risk in West Africans